Skip to main content

Table 4 Univariate and multivariate analysis with respect to progression free survival in 61 triple-negative and 45 HER2-positive breast cancers

From: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Parameters

Univariate analysis

Multivariate analysis

Hazard ratio

95% CI

p value

Hazard ratio

95% CI

p value

TNBC (n = 61)

 Lymph node status

  Positive vs negative

0.942

0.203–4.359

0.939

1.303

0.216–7.854

0.773

 Ki67

  ≤ 14% vs > 14%

0.739

0.216–2.526

0.630

1.866

0.395–8.817

0.431

 Pathological response

  pCR vs non-pCR

0.234

0.050–1.084

0.063

0.722

0.103–5.057

0.743

 PD-1

  Positive vs negative

3.318

1.011–10.891

0.048

0.869

0.177–4.265

0.863

 PD-L1

  Positive vs negative

8.375

1.807–38.812

0.007

9.479

1.092–82.320

0.041

HER2+BC (n = 45)

 Lymph node status

  Positive vs negative

0.603

0.318–1.145

0.122

0.641

0.318–1.294

0.215

 Ki67

  ≤ 14% vs > 14%

0.714

0.385–1.326

0.286

0.730

0.371–1.436

0.362

 Pathological response

  pCR vs non-pCR

0.670

0.358–1.254

0.210

0.912

0.428–1.944

0.811

 PD-1

  Positive vs negative

1.990

0.585–6.766

0.271

1.333

0.114–15.527

0.819

 PD-L1

  Positive vs negative

1.934

0.651–5.738

0.235

1.568

0.187–13.175

0.679

  1. TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, CI confidence interval, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us